X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.
Lead Product(s): CAR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Xenetic Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 11, 2022
Details:
Seclidemstat (SP-2577), a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Salarius Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
